Ann: FDA Clears PYC to Commence First Human Trials in RP11, page-84

first dose = having drug design/manufacture of large batches squared away

it’ll be a historic moment for the company and the team. We can’t afford any delays given our cash runway, and we can’t have a repeat of the 2 year IND approval delay.

Market is a weighing machine in the long run, hopefully we can start shedding our reputation for untimely delivery and starting achieving a string of value accretive milestones. The BD opportunities will materialize in time as we build the scientific, regulatory and commercial/clinical body of evidence (data and capability).